BCYC
Price
$6.16
Change
-$0.09 (-1.44%)
Updated
Nov 20, 04:59 PM (EDT)
Capitalization
428M
103 days until earnings call
Intraday BUY SELL Signals
INSM
Price
$199.68
Change
-$3.88 (-1.91%)
Updated
Nov 20, 04:59 PM (EDT)
Capitalization
42.59B
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs INSM

Header iconBCYC vs INSM Comparison
Open Charts BCYC vs INSMBanner chart's image
Bicycle Therapeutics
Price$6.16
Change-$0.09 (-1.44%)
Volume$2K
Capitalization428M
Insmed
Price$199.68
Change-$3.88 (-1.91%)
Volume$40.44K
Capitalization42.59B
BCYC vs INSM Comparison Chart in %
BCYC
Daily Signal:
Gain/Loss:
INSM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCYC vs. INSM commentary
Nov 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and INSM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 21, 2025
Stock price -- (BCYC: $6.17 vs. INSM: $199.68)
Brand notoriety: BCYC and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 127% vs. INSM: 110%
Market capitalization -- BCYC: $428M vs. INSM: $42.59B
BCYC [@Biotechnology] is valued at $428M. INSM’s [@Biotechnology] market capitalization is $42.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.15B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • INSM’s FA Score: 1 green, 4 red.
According to our system of comparison, INSM is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • INSM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BCYC and INSM are a good buy in the short-term.

Price Growth

BCYC (@Biotechnology) experienced а -6.52% price change this week, while INSM (@Biotechnology) price change was +4.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.65%. For the same industry, the average monthly price growth was -7.08%, and the average quarterly price growth was +60.39%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 03, 2026.

INSM is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-1.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($42.6B) has a higher market cap than BCYC($428M). INSM YTD gains are higher at: 189.224 vs. BCYC (-55.929). BCYC has higher annual earnings (EBITDA): -245.86M vs. INSM (-1.09B). INSM has more cash in the bank: 1.68B vs. BCYC (648M). BCYC has less debt than INSM: BCYC (5.74M) vs INSM (576M). INSM has higher revenues than BCYC: INSM (447M) vs BCYC (28.3M).
BCYCINSMBCYC / INSM
Capitalization428M42.6B1%
EBITDA-245.86M-1.09B23%
Gain YTD-55.929189.224-30%
P/E RatioN/AN/A-
Revenue28.3M447M6%
Total Cash648M1.68B39%
Total Debt5.74M576M1%
FUNDAMENTALS RATINGS
BCYC vs INSM: Fundamental Ratings
BCYC
INSM
OUTLOOK RATING
1..100
5918
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
1002
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
8635
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (13) in the null industry is significantly better than the same rating for INSM (79) in the Biotechnology industry. This means that BCYC’s stock grew significantly faster than INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (2) in the Biotechnology industry is significantly better than the same rating for BCYC (100) in the null industry. This means that INSM’s stock grew significantly faster than BCYC’s over the last 12 months.

BCYC's SMR Rating (94) in the null industry is in the same range as INSM (99) in the Biotechnology industry. This means that BCYC’s stock grew similarly to INSM’s over the last 12 months.

INSM's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for BCYC (86) in the null industry. This means that INSM’s stock grew somewhat faster than BCYC’s over the last 12 months.

INSM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that INSM’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCINSM
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 2 days ago
70%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 17 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signal:
Gain/Loss:
INSM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIGHX33.73N/A
N/A
JHancock International Growth NAV
CGEOX20.15N/A
N/A
Calamos Global Equity R6
UIVPX12.79N/A
N/A
MFS Intrinsic Value R3
FGFCX40.74N/A
N/A
Federated Hermes International Leaders C
SCAVX13.90N/A
N/A
AB Small Cap Value A

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RPTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-1.28%
RPTX - BCYC
50%
Loosely correlated
-2.33%
NRIX - BCYC
43%
Loosely correlated
+6.98%
RGNX - BCYC
43%
Loosely correlated
-0.59%
AUTL - BCYC
42%
Loosely correlated
-3.15%
BHVN - BCYC
42%
Loosely correlated
+1.80%
More